Lyell Immunopharma annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Lyell Immunopharma Stock-Based Compensation Growth & History (LYEL)
Lyell Immunopharma's stock-based compensation was $41.8M for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $41.8M | $8.7M | +26.20% |
| 2024 | 2024-12-31 | $33.1M | −$13.9M | −29.61% |
| 2023 | 2023-12-31 | $47.1M | −$34.8M | −42.53% |
| 2022 | 2022-12-31 | $81.9M | $19.7M | +31.71% |
| 2021 | 2021-12-31 | $62.2M | $28.9M | +87.01% |
| 2020 | 2020-12-31 | $33.3M | $17.5M | +111.42% |
| 2019 | 2019-12-31 | $15.7M | — | — |
Lyell Immunopharma quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.5M | −$472,000 | −9.43% |
| Q1 2026 | 2026-03-31 | $4.3M | −$1.7M | −28.70% |
| Q4 2025 | 2025-12-31 | $25.6M | $17.5M | +216.33% |
| Q3 2025 | 2025-09-30 | $5.2M | −$2.4M | −31.36% |
| Q2 2025 | 2025-06-30 | $5.0M | −$3.3M | −39.59% |
| Q1 2025 | 2025-03-31 | $6.0M | −$3.1M | −34.20% |
| Q4 2024 | 2024-12-31 | $8.1M | −$380,000 | −4.49% |
| Q3 2024 | 2024-09-30 | $7.6M | −$2.9M | −27.52% |
| Q2 2024 | 2024-06-30 | $8.3M | −$5.9M | −41.76% |
| Q1 2024 | 2024-03-31 | $9.2M | −$4.7M | −34.05% |
| Q4 2023 | 2023-12-31 | $8.5M | −$9.9M | −53.91% |
| Q3 2023 | 2023-09-30 | $10.5M | −$8.6M | −45.01% |
| Q2 2023 | 2023-06-30 | $14.2M | −$8.2M | −36.53% |
| Q1 2023 | 2023-03-31 | $13.9M | −$8.1M | −36.98% |
| Q4 2022 | 2022-12-31 | $18.4M | −$2.8M | −13.29% |
| Q3 2022 | 2022-09-30 | $19.1M | $6.1M | +46.63% |
| Q2 2022 | 2022-06-30 | $22.4M | $7.2M | +46.96% |
| Q1 2022 | 2022-03-31 | $22.0M | $9.3M | +73.01% |
| Q4 2021 | 2021-12-31 | $21.2M | — | — |
| Q3 2021 | 2021-09-30 | $13.0M | $3.3M | +33.79% |
| Q2 2021 | 2021-06-30 | $15.2M | $8.0M | +109.81% |
| Q1 2021 | 2021-03-31 | $12.7M | — | — |
| Q3 2020 | 2020-09-30 | $9.7M | — | — |
| Q2 2020 | 2020-06-30 | $7.3M | — | — |
Lyell Immunopharma stock-based compensation trends
Over the last five fiscal years, Lyell Immunopharma's stock-based compensation increased from $33.3M to $41.8M, a change of $8.6M. The latest reported quarter, Q2 2026, shows $4.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma source filings ↗